Recombinant CD39 anticorps
Aperçu rapide pour Recombinant CD39 anticorps (ABIN7880667)
Antigène
Voir toutes CD39 (ENTPD1) AnticorpsType d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
Clone
-
-
Fonction
- CD39 Antibody / ENTPD1
-
Purification
- Affinity purified
-
Immunogène
- A synthetic peptide specific to ENTPD1 protein was used as the immunogen for the CD39 antibody.
-
Isotype
- IgG
-
-
-
-
Indications d'application
- Optimal dilution of the CD39 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Buffer
- Antibody in PBS with 0.02 % sodium azide, 50 % glycerol and 0.4-0.5 mg/mL BSA
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
- -20 °C
-
Stockage commentaire
- Store the CD39 antibody at -20oC.
-
-
- CD39 (ENTPD1) (Ectonucleoside Triphosphate diphosphohydrolase 1 (ENTPD1))
-
Autre désignation
- CD39
-
Sujet
-
CD39 antibody is a widely used reagent for studying immune regulation, purinergic signaling, and vascular biology. The encoded protein, CD39 (also known as ectonucleoside triphosphate diphosphohydrolase 1 or ENTPD1), is an ectoenzyme expressed on the surface of endothelial cells, immune cells, and platelets. CD39 hydrolyzes extracellular ATP and ADP into AMP, which can then be converted into adenosine by CD73. This ATP-adenosine pathway regulates inflammation, thrombosis, and tissue homeostasis by balancing proinflammatory and immunosuppressive signals.
In the immune system, CD39 plays an important role in controlling T cell and regulatory T cell activity. By reducing extracellular ATP levels and increasing adenosine production, CD39 dampens inflammatory responses and promotes immune tolerance. High CD39 expression on regulatory T cells contributes to their immunosuppressive capacity, making CD39 a focus of interest in autoimmune disease, transplantation, and cancer immunology. In the vascular system, CD39 helps prevent platelet aggregation and thrombosis by degrading platelet-activating nucleotides, thereby maintaining vascular health.
Dysregulation of CD39 expression or activity has been implicated in diverse diseases. Increased CD39 activity has been observed in tumors, where it contributes to immune evasion by creating an adenosine-rich, immunosuppressive microenvironment. Conversely, reduced CD39 function has been linked to heightened inflammation in autoimmune diseases and transplant rejection. These associations underscore CD39 as both a biomarker and a therapeutic target across multiple areas of biomedical research.
At the molecular level, CD39 is a transmembrane glycoprotein with two transmembrane domains and large extracellular loops that contain conserved apyrase motifs responsible for nucleotide hydrolysis. Its enzymatic activity is dependent on divalent cations such as calcium and magnesium. By regulating extracellular nucleotide concentrations, CD39 serves as a critical checkpoint in purinergic signaling pathways that influence vascular tone, immune cell communication, and tissue repair.
The CD39 antibody is commonly used in flow cytometry, western blotting, immunohistochemistry, and immunofluorescence to detect protein expression and distribution. These applications are valuable for research in immunology, oncology, and cardiovascular biology. For scientists investigating immune regulation, thrombosis, or purinergic signaling, the CD39 antibody provides a specific and dependable detection tool. NSJ Bioreagents supplies validated antibodies designed to ensure reproducibility and accuracy in advanced molecular studies. -
UniProt
- P49961
Antigène
-